DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n3mnfs/prefeasibility) has announced the addition of the "Pre-Feasibility ...
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback